argenex (NASDAQ:ARGX) Given New $1,025.00 Price Target at Royal Bank Of Canada

argenex (NASDAQ:ARGX) had its price objective upped by analysts at Royal Bank Of Canada from $945.00 to $1,025.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price would indicate a potential upside of 11.41% from the stock’s previous close.

Several other equities analysts also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $940.00 target price on shares of argenex in a research report on Thursday, June 25th. Citizens Jmp dropped their price target on argenex from $944.00 to $932.00 and set a “market outperform” rating for the company in a report on Friday. Guggenheim boosted their price target on argenex from $1,135.00 to $1,185.00 and gave the company a “buy” rating in a research note on Friday. Bank of America upped their price objective on argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. Finally, Weiss Ratings raised argenex from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,049.22.

argenex Trading Down 0.5%

Shares of NASDAQ:ARGX traded down $4.54 on Friday, hitting $920.06. The company had a trading volume of 167,142 shares, compared to its average volume of 353,368. The stock has a market cap of $57.56 billion, a price-to-earnings ratio of 40.93, a P/E/G ratio of 1.05 and a beta of 0.45. The stock has a 50 day moving average price of $865.90 and a 200 day moving average price of $814.39. argenex has a 1-year low of $587.37 and a 1-year high of $953.58.

argenex (NASDAQ:ARGX) last posted its earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.86 by $1.46. argenex had a net margin of 31.31% and a return on equity of 44.37%. The company had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Sell-side analysts anticipate that argenex will post 26.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC increased its holdings in argenex by 32.1% in the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after buying an additional 122 shares during the period. NewEdge Advisors LLC boosted its position in shares of argenex by 5,962.5% during the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after acquiring an additional 1,431 shares in the last quarter. Focus Partners Wealth boosted its position in shares of argenex by 22.3% during the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after acquiring an additional 73 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after acquiring an additional 99 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in argenex by 60.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock valued at $73,000 after acquiring an additional 50 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Trending Headlines about argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported Q2 results that beat expectations, with EPS of $7.32 versus $5.86 expected and revenue of $1.54 billion versus $1.45 billion estimated, reinforcing confidence in the company’s growth and profitability. argenx reports quarterly earnings
• Positive Sentiment: Vyvgart sales jumped sharply in the second quarter, with multiple reports highlighting roughly 60% year-over-year growth, which supports the investment case for argenx’s core autoimmune franchise. Reuters article on Vyvgart sales
• Positive Sentiment: Guggenheim raised its price target on argenx from $1,135 to $1,185 and reiterated a Buy rating, signaling confidence in further upside after the earnings update. Benzinga analyst update
• Neutral Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932 while maintaining a Market Outperform rating, suggesting continued optimism but a bit less enthusiasm than before. Benzinga analyst update
• Neutral Sentiment: Recent earnings-call coverage and business-update articles point to upcoming pipeline readouts, which could add catalysts but also create event risk. Business Insider update

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.